Table 3.
Comparative between cured and non-cured patients with sporotrichosis treated with Amphotericin B at the Evandro Chagas National Institute of Infectious Diseases (INI/FIOCRUZ) from 1998 to 2018.
| Outcome | Cured | Non-Cured | p Value |
|---|---|---|---|
| N | 38 | 35 | |
| Symptoms duration until treatment started a (days) | 60.00 [15.00, 2190.00] | 120.00 [20.00, 365.00] | 0.037 |
| Positive hemoculture for sporotrichosis | 0 (0.0%) | 6 (17.1%) | - b |
| CNS involvement | 4 (10.5%) | 11 (31.4%) | 0.041 |
| Low compliance to treatment | 11 (28.9%) | 21 (61.8%) | 0.009 |
| Total dose of amphotericin B (Lipid formulation) a (mg) | 3750.00 [200.00, 10,000.00] | 5225.00 [250.00, 14,700.00] | 0.024 |
| Total dose of amphotericin B (Deoxycholate) a (mg) |
575.00 [50.00, 11,250.00] | 1200.00 [50.00, 5390.00] | 0.120 |
a Median and range; b p value was not calculated due to zero count for cured patients; p values < 0.05 are highlighted in bold. CNS: Central nervous system.